Previous studies have reported that rebiopsy could provide further information, including histological or genetic changes that might be helpful in optimizing the next treatment24, 25; however, little clinical data exists regarding the prognostic impact of rebiopsy on ALK‐positive NSCLC patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.